Advanced in Desmoplastic Small Round Cell Tumor

Dr. Robin L. Jones

Oncology
825 Eastlake Ave E, 
Seattle, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Desmoplastic Small Round Cell Tumor
825 Eastlake Ave E, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robin Jones is an Oncologist in Seattle, Washington. Dr. Jones is rated as an Advanced provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

His clinical research consists of co-authoring 372 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Desmoplastic Small Round Cell Tumor.

Specialties
Oncology
Licenses
Internal Medicine in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
A Phase 2 Study of Oraxol in Subjects With Cutaneous Angiosarcoma
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Drug
Study Drug: Oraxol
Study Phase: Phase 2
Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients
Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients
Enrollment Status: Completed
Publish Date: May 15, 2023
Intervention Type: Other
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

370 Total Publications

Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
Journal: JAMA oncology
Published: October 16, 2025
Similar Doctors
Distinguished in Desmoplastic Small Round Cell Tumor
Dr. Heidi J. Gray
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Desmoplastic Small Round Cell Tumor
Dr. Heidi J. Gray
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-598-4333
Languages Spoken:
English, French, Malagasy, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Heidi Gray is a Gynecologic Oncologist and an Oncologist in Seattle, Washington. Dr. Gray is rated as a Distinguished provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Sertoli-Leydig Cell Tumor, Hysterectomy, and Oophorectomy. Dr. Gray is currently accepting new patients.

Advanced in Desmoplastic Small Round Cell Tumor
Dr. Elizabeth T. Loggers
Oncology | Hematology
Advanced in Desmoplastic Small Round Cell Tumor
Dr. Elizabeth T. Loggers
Oncology | Hematology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Korean, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Loggers is an Oncologist and a Hematologist in Seattle, Washington. Dr. Loggers is rated as an Elite provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. Her top areas of expertise are Adult Soft Tissue Sarcoma, Epithelioid Sarcoma, Liposarcoma, Angiosarcoma, and Liver Embolization. Dr. Loggers is currently accepting new patients.

Advanced in Desmoplastic Small Round Cell Tumor
Dr. Jane M. Borkowski
Hematology Oncology | Hematology | Oncology
Advanced in Desmoplastic Small Round Cell Tumor
Dr. Jane M. Borkowski
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English, Castilian, Czech, French, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jane Borkowski is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Borkowski is rated as an Advanced provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. Her top areas of expertise are Paget Disease of the Breast, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Familial Colorectal Cancer. Dr. Borkowski is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jones's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile